I Did Mushrooms for Science, Pt. 1
Why It Matters
Demonstrating quantifiable health‑span effects from psychedelics could reshape drug development priorities, opening a lucrative frontier for longevity‑focused biotech ventures.
Key Takeaways
- •Five grams of psilocybin taken under extensive biomarker monitoring.
- •249 blood and brain markers measured before, during, after trip.
- •Kernel Flow wearable provides daily brain activity data throughout experiment.
- •Researchers aim to link psychedelics with longevity and rejuvenation.
- •Potential risks include overwhelming experience and lasting psychological impact.
Summary
The video documents a self‑experiment in which the host ingests a five‑gram dose of psilocybin mushrooms while subjecting himself to an unprecedented suite of measurements. Over the course of the trial, 249 blood‑based biomarkers and continuous brain activity via the Kernel Flow wearable are recorded before the dose, at the peak of the psychedelic experience, and during the post‑trip recovery period. The core objective is to detect any signals of cellular rejuvenation or longevity benefits that recent mouse and human‑cell studies have hinted at. By pairing a full‑panel blood analysis with daily brain scans, the team hopes to capture subtle physiological shifts that traditional studies have missed, effectively creating the most data‑rich psychedelic trip ever logged. Throughout the session, the host emphasizes the novelty of the approach—calling it “the most measured psychedelic trip in history”—and shares candid reflections on the anticipated intensity of a five‑gram dose. He also acknowledges concerns from peers about potential psychological fallout, underscoring the experiment’s high‑stakes nature. If the data reveal measurable health‑span improvements, the findings could pivot the narrative around psychedelics from recreational or psychiatric therapy toward a broader longevity platform, prompting biotech firms and investors to explore new therapeutic avenues.
Comments
Want to join the conversation?
Loading comments...